Title: Central Retinal Venous Occlusion Following Intravenous Immunoglobulin Therapy-A Case Report
Authors: Dr Prathyusha Gottapu, Dr Sreenivas S, Dr Avinash K
DOI: https://dx.doi.org/10.18535/jmscr/v8i2.161
Abstract
IV immunoglobulins has been widely used in a variety of diseases, including primary and secondary immunodeficiency diseases, neuromuscular diseases, Guillain-Barré syndrome and Kawasaki disease. Although a large number of clinical trials have demonstrated that immunoglobulin is effective and well tolerated, various adverse effects have been reported. The majority of these events, such as flushing, headache, malaise, fever, chills, fatigue and lethargy, are transient and mild. However, some rare side effects, including renal impairment, thrombosis, arrhythmia, aseptic meningitis, hemolyticanemia, and transfusion-related acute lung injury (TRALI), are serious. IVIg treatment can cause thrombotic complications. Five cases of stroke, two cases of deep vein thrombosis, seven myocardial infarctions, one case each of RVO and pulmonary embolism have so far been described with IVIg. The rate of thrombotic complications following IVIg may be as high as 3-5% though underreported and can involve both arterial and venous circulation. In this case we describe a patient with Guillain Barré syndrome (GBS) who experienced retinal vein occlusion (RVO) following IVIg therapy.
Keywords: Guillian barre syndrome, central retinal vein occlusion, IVIG Intravenous immunoglobulins.
References
- Dynckpj, Prineas J. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PI, Thomas PK, Griffin JW, et al. editors. Peripheral neuropathy. 3rd ed. Philadelphia: Saunders, 1993:1498-517.
- Oh KT, Boldt HC, Dansi RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997;124:416-8.
- McGrath MA, Wechsler F, Hunyor ABL, Penny R. Systemic factors contributing to retinal vein occlusion. Arch Intern Med 1978;138:216-20.
- Schussler 0, Lantoine F, Devynck MA, Glotz D, David Dufilho M. Human immunoglobulins inhibit thrombin induced Ca2+ movements and nitric oxide production in endothelial cells. J BioI Chern 1996;271:26473-6.
- Bagdasarian A, Tonetta S, Harel W, Mamidi R. Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998;74:74-82.
- Emerson GG, Herndon CN, Sreih Thrombotic Complications after Intravenous Immunoglobulin Therapy in Two Patients (http://emedicine.medscape.com)
- Woodruff RK, Grigg AP, Firkin FC, Smith Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients [letter]. Lancet.
- Oh KT, Boldt C, Danis Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. American Journal of Ophthalmology 1997; 124: 416- 8. 6.
- Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak Pulmonary embolism after intravenous immunoglobulin. Journal of Royal Society of Medicine 2001; 94: 187-8. 7.
- Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high-dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases. Annals of Rheumatic Diseases 2000; 59: 77-80.